ストックスクリーナーアプリを入手
1.80
5.76%
-0.11
前日終値:
$1.91
開ける：
$1.94
24時間の取引高:
3.97M
Relative Volume:
1.88
時価総額：
$392.73M
収益：
$194.75M
当期純損益:
$-51.26M
株価収益率:
-6.4286
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
-15.49%
1か月 パフォーマンス:
-24.05%
6か月 パフォーマンス:
+20.81%
1年 パフォーマンス:
+26.76%
1日の値動き範囲:
$1.78
$1.94
1週間の範囲:
$1.78
$2.14
52週間の値動き範囲:
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
名前
Akebia Therapeutics Inc
セクター
電話
617-871-2098
住所
245 FIRST STREET, CAMBRIDGE, MA
AKBA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.80 | 392.73M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-29 | 再開されました | BTIG Research | Buy |
| 2023-08-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-31 | ダウングレード | Needham | Buy → Hold |
| 2022-03-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 繰り返されました | Needham | Buy |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-02 | 開始されました | JP Morgan | Overweight |
| 2019-03-20 | 開始されました | Citigroup | Neutral |
| 2018-09-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 繰り返されました | Needham | Buy |
| 2018-06-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-12-19 | 開始されました | Piper Jaffray | Overweight |
| 2017-12-07 | 開始されました | BTIG Research | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | Needham | Buy |
| 2016-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-12-20 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-15 | 開始されました | Aegis Capital | Buy |
| 2016-09-29 | 開始されました | Brean Capital | Buy |
| 2016-03-16 | 繰り返されました | Needham | Buy |
| 2016-01-21 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Akebia Therapeutics Inc (AKBA) 最新ニュース
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 19.7% - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Upgraded to Hold at StockNews.com - MarketBeat
Akebia Therapeutics extends loan agreement, receives $9.3M - MSN
Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline - Seeking Alpha
Akebia Therapeutics, Inc. (NASDAQ:AKBA) CEO John P. Butler Sells 144,250 Shares - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Insider Sells $116,804.10 in Stock - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Sells $106,062.60 in Stock - MarketBeat
Insider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Sells 30,202 Shares of Stock - MarketBeat
Akebia Therapeutics extends loan agreement, receives $9.3M By Investing.com - Investing.com Canada
$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 - GlobeNewswire
$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 by Type, End Use and RegionAkebia Therapeutics, ABB, Aethon, Omron Corp., and Amazon Lead the Competition - Yahoo Finance
Akebia Therapeutics' chief accounting officer sells $63,424 in stock - MSN
Akebia Therapeutics' chief commercial officer sells $116,804 in stock - MSN
Akebia therapeutics' chief medical officer sells $106,062 in stock By Investing.com - Investing.com South Africa
Akebia therapeutics' chief medical officer sells $106,062 in stock - MSN
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics CEO John Butler sells $302,925 in stock By Investing.com - Investing.com Canada
Akebia Therapeutics' chief commercial officer sells $116,804 in stock By Investing.com - Investing.com South Africa
Akebia's Latest Talent Investment: Strategic Options Grant Details Revealed - StockTitan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Increase in Short Interest - MarketBeat
Akebia Therapeutics CEO John Butler sells $302,925 in stock - MSN
SEC Form S-8 filed by Akebia Therapeutics Inc. - Quantisnow
Akebia Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Akebia Therapeutics (NASDAQ:AKBA) Trading 10.9% HigherTime to Buy? - MarketBeat
H.C. Wainwright maintains Akebia stock Buy rating, $7.50 target - MSN
Akebia Therapeutics (NASDAQ:AKBA) Trading Down 4.4%What's Next? - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified - Simply Wall St
Better Luck Next Year: US FDA CRLs May Be Rising, But Are Not The End Of The Story - News & Insights
Akebia Therapeutics (NASDAQ:AKBA) Trading Up 10.9%Here's What Happened - MarketBeat
Lobbying Update: $240,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Bought by Barclays PLC - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
What is HC Wainwright's Forecast for AKBA FY2024 Earnings? - MarketBeat
Equities Analysts Issue Forecasts for AKBA FY2024 Earnings - Defense World
FY2024 Earnings Forecast for AKBA Issued By HC Wainwright - MarketBeat
Analysts Offer Predictions for AKBA FY2029 Earnings - MarketBeat
Brokers Issue Forecasts for AKBA FY2029 Earnings - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from HC Wainwright - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Sell at StockNews.com - MarketBeat
Akebia Therapeutics Inc (AKBA) 財務データ
収益
当期純利益
現金流量
EPS
3.23%
3.94%
大文字化:
|
ボリューム (24 時間):